Workflow
奥驰亚集团(MO)
icon
搜索文档
Altria Enters Memorandum of Understanding With KT&G to Pursue Long-term Adjacent Growth
Businesswire· 2025-09-23 07:15
RICHMOND, Va.--(BUSINESS WIRE)---- $MO #Altria--Altria Enters Memorandum of Understanding With KT&G to Pursue Long-Term Adjacent Growth. ...
Building A $100,000 Dividend Portfolio: Maximizing SCHD's Income With September's Top High-Yield Stocks
Seeking Alpha· 2025-09-22 20:00
投资组合构建策略 - 投资组合旨在通过股息产生额外收入 重点关注具有显著竞争优势和强劲财务的公司 以提供有吸引力的股息收益率和股息增长 [1] - 结合高股息收益率和高股息增长公司 逐步减少对整体股市波动的依赖 [1] - 通过跨行业和跨板块的多元化配置 降低投资组合波动性和风险 [1] 投资工具与风险控制 - 投资组合通常由交易所交易基金和个别公司股票混合组成 强调广泛多元化和风险降低 [1] - 建议纳入低贝塔系数的公司 有助于降低投资组合的整体风险水平 [1] - 选股过程精心策划 优先追求总回报 包括资本利得和股息 而非孤立地仅关注股息 [1] 分析师持仓披露 - 分析师通过股票所有权、期权或其他衍生品 长期持有MO、BBSEY、CVX、SHEL、TTE、VZ、ZURVY、VICI、GOOGL、AXAHY、MSFT、SCHD、PEP、RQI等公司的多头头寸 [2]
Altria Delivers 7.2% EPS Growth in 1H25 Despite Sales Headwinds
ZACKS· 2025-09-22 15:00
Key Takeaways Altria posted 7.2% H1 EPS growth to $2.67, with Q2 EPS up 8.3% year over year to %1.44.Revenues fell 3.6% to $11.4B, but smokeable products' margins rose 3.5 points to 64.5%.Altria returned over $4B to shareholders through buybacks and dividends.Altria Group, Inc. ((MO) delivered a notable earnings performance in the first half of 2025, achieving 7.2% adjusted earnings per share (EPS) growth despite ongoing sales pressure. Adjusted EPS rose to $2.67 compared to $2.49 in the same period last ye ...
Altria: On! Sustains Rich Dividend Story As NJOY Fades Into Background
Seeking Alpha· 2025-09-19 13:13
I am a full-time analyst interested in a wide range of stocks. With my unique insights and knowledge, I hope to provide other investors with a contrasting view of my portfolio, given my particular background.If you have any questions, feel free to reach out to me via a direct message on Seeking Alpha or leave a comment on one of my articles.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the ...
8 Dividend Growth Stocks Every Investor Should Consider
The Motley Fool· 2025-09-19 09:45
核心观点 - 真正的收益投资机会来自股息增长率超越通胀且保留充足现金再投资的公司而非高股息率但缺乏增长的标的 [1][2] - 八家股息增长型公司平均连续51年提高股息多数估值合理但未被市场充分关注 [2] 帕克汉尼汾(Parker-Hannifin) - 工业自动化领域龙头五年股息增长率达14.3%远超多数科技股 [4] - 股息支付率仅24.6%为未来增长留足空间连续69年提高股息 [4] - 当前股息率0.97%为同类企业中最低水平之一 [4] 宝洁(Procter & Gamble) - 将家用产品转化为抗通胀工具当前股息率2.64%支付率62% [5] - 五年股息增长率6%连续69年提高股息涵盖1957年以来所有衰退周期 [5] 可口可乐(Coca-Cola) - 全球饮料垄断企业连续63年提高股息当前股息率3.03% [6] - 五年股息增长率4.3%支付率70.5%新兴市场与高端产品驱动增量增长 [6][7] - 强大护城河确保稳定自由现金流与股东可靠收益 [7] 强生(Johnson & Johnson) - 医药与医疗器械业务产生稳定现金流股息率2.93%支付率53.4% [8] - 五年股息年均增长率5.3%连续63年提高股息 [8] - 每年投入数十亿美元药物研发为医疗行业最可靠收益股之一 [8] 奥驰亚(Altria Group) - 股息率6.5%支付率78.9%依靠定价权维持高水平稳定分红 [9] - 五年股息增长率4.04%在卷烟销量年降5%背景下实现精准定价策略 [9] 劳氏公司(Lowe's Companies) - 五年股息增长率16.9%股息率1.79%侧重增长而非收益 [10] - 支付率38.1%连续25年提高股息穿越房地产周期波动 [10] - 住房交易量回升背景下仍具持续增长空间 [10] 固安捷(W.W. Grainger) - 工业维修耗材供应商股息率0.91%支付率21.3% [11] - 五年股息年增长率8.06%连续54年提高股息 [11] - 工厂医院及办公楼日常依赖其供应基础业务具防御性 [11] 雅培(Abbott Laboratories) - 医疗设备创新企业五年股息年均增长率10.6%显著高于行业 [12] - 股息率1.76%支付率28.6%留足扩张空间 [12] - FreeStyle Libre连续血糖监测系统主导美国以外市场连续53年提高股息 [12]
High Dividend Yields: How Altria (MO) Earned its Spot as Best Performing in 2025 Dividend Stock
Yahoo Finance· 2025-09-18 19:25
Altria Group, Inc. (NYSE:MO) is included among the 15 Best Performing Dividend Stocks So Far in 2025. High Dividend Yields: How Altria (MO) Earned its Spot as Best Performing in 2025 Dividend Stock mmoktp/Shutterstock.com Altria Group, Inc. (NYSE:MO) is among the world’s biggest tobacco companies, owning popular brands such as Marlboro, Black & Mild, Parliament, Copenhagen, and Skoal. While some investors may hesitate to back a tobacco business, those who do are usually drawn by its exceptionally high a ...
Altria Stock Trading at a Discount: What's the Next Best Move?
ZACKS· 2025-09-17 17:11
Key Takeaways Altria trades at a forward P/E of 11.76, below industry peers and the S&P 500 average.Q2 EPS rose 8.3% to $1.44, driven by higher pricing, efficiencies, and buybacks.on! shipments surged 26.5%, boosting oral tobacco share and segment income growth.Altria Group, Inc. ((MO) is currently trading at a compelling discount relative to both its industry peers and the broader market, positioning it as a potential value opportunity for long-term investors. The stock’s forward 12-month price-to-earnings ...
Altria Is One of the Top Dividend Stocks Investors Can Buy in September
Yahoo Finance· 2025-09-16 20:20
Key Points Altria has increased its dividend annually for 56 consecutive years. The company has pricing power that allows it to offset declining volume. 10 stocks we like better than Altria Group › The average American may not know the name Altria (NYSE: MO), but there's a good chance that they know some of its brands. The tobacco giant owns brands such as Marlboro, Copenhagen, Black & Mild, Skoal, Parliament, and a handful of others. For decades, the stock has been a mainstay of the market, with p ...
Altria Returns $4 Billion to Shareholders in First Half of 2025
ZACKS· 2025-09-16 14:35
资本回报策略 - 2025年上半年通过股息和股票回购向股东返还超过40亿美元 突显公司稳定现金流生成能力[1] - 股息分配35亿美元 维持将大部分收益支付给股东的长期政策[2] - 以平均价格57.71美元回购1040万股 总计投入6亿美元 其中第二季度以274万美元回购470万股[2] - 10亿美元股票回购计划中剩余4亿美元额度 预计在2025年底前完成[2] 财务健康状况 - 截至2025年6月30日 总债务与EBITDA比率为2.0倍 符合公司目标 提供财务灵活性[3] - 稳健的资产负债表支持持续股东回报 同时保持稳定的杠杆状况和纪律性财务管理[3] 同业比较分析 - 菲利普莫里斯国际公司((PM))专注于无烟产品扩张而非资本回报 重点发展IQOS、ZYN和VEEV等关键品牌[5] - 菲利普莫里斯目标到2026年实现净债务与调整后EBITDA比率约2.0倍以支持可持续增长[5] - Turning Point Brands((TPB))报告总债务3亿美元 净债务1.901亿美元 现金1.099亿美元 期间未进行股票回购[6] - Turning Point Brands将资本导向战略举措 专注于扩大市场存在感和增强产品供应[6] 股价表现与估值 - 过去一个月股价下跌1.7% 同期行业下跌0.4%[7] - 远期市盈率11.77倍 低于行业平均的15.21倍[10] - 2025年收益预计同比增长5.3% 2026年预计增长2.9%[11] - 2025年第四季度每股收益共识估计1.32美元 2026年第三季度估计1.42美元[12] - 2025年全年每股收益共识估计5.39美元 2026年估计5.55美元[12] 管理层信心与投资定位 - 资本回报举措显示管理层对烟草和无烟产品组合现金流状况的信心[4] - 40亿美元里程碑强调可预测性 巩固其作为消费品行业最可靠收益投资标的之一的地位[4]
Big Tobacco Isn’t Up in Smoke Just Yet
Yahoo Finance· 2025-09-15 10:30
行业表现 - 全球六大烟草股年内平均总回报达43% [6] - 行业在1900年至2015年间表现优于美国所有其他板块 [4] - 菲利普莫里斯国际和奥驰亚股价年内分别上涨超37%和27% [6] 产品与监管 - FDA加速审批四大行业领先企业的尼古丁袋产品 预计12月前完成 [3] - 菲利普莫里斯国际旗下Zyn品牌20种口味获FDA批准 审批历时五年 [2] - 行业采取"先上市后获批"策略 尤其针对含合成尼古丁产品 [3] 销售数据 - Zyn在美洲市场推动无烟口服产品出货量突破2亿罐 同比增长32% [6] - 奥驰亚旗下竞品on!出货量同比增长26% [6] - 非香烟类产品今年销售表现尤为强劲 [1] 财务影响 - 美国烟草公司同意向52个州和市政支付2060亿美元 期限25年 [4] - 约半数市政将支付款证券化为市政债券 收益超标普市政债券指数2.5倍 [4]